

1300 Eye Street N.W.
Washington, DC 20005
Telephone: 202.659.0100
Facsimile: 202.659.0105
www.novakdruce.com

**Novak Druce DeLuca
& Quigg, LLP**

**RECEIVED
CENTRAL FAX CENTER**

JUL 10 2006

Facsimile

To:	USPTO – Mail Stop Amendment	From:	James Remenick
Fax:	(571) 273-8300	Pages:	4
Phone:	(571) 272-1000	Date:	July 10, 2006
Re:		cc:	

☐ Urgent ☐ For Review ☐ Please Comment ☐ Please Reply ☐ Please Recycle

• **Comments:**

In re Application of: WENZEL et al.

Serial No.: 09/782,306

Attorney Docket No.: PF 51202

Confirmation No.: 2453

Filing Date: 02/14/2001

Attachments: Response to the Office Action of April 10, 2006

CONFIDENTIALITY NOTICE: This facsimile and any attachments contain information from the law firm of Novak Druce DeLuca & Quigg, LLP, which may be confidential and/or privileged. The information is intended to be for the use of the individual or entity named on this facsimile. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you receive this facsimile in error, please notify us by reply facsimile immediately so that we can arrange for the retrieval of the original documents at no cost to you.

JUL 10 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION

OF: WENZEL ET AL.

SERIAL No. 09/782,306

FILED: FEBRUARY 14, 2001

FOR: NOVEL USE OF FLAVONES

DOCKET No.: PF 51202

CONFIRMATION No.: 2453

GROUP ART UNIT: 1623

EXAMINER: D. KHARE

Honorable Commissioner
for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being
facsimile transmitted on the date indicated below to
Commissioner of Patents and Trademarks, Alexandria,
Va 22313-1450, at: (571) 273-8300

Extension No.
or is being deposited with the United States Postal
Service with sufficient postage as first class mail
in an envelope addressed to Commissioner for Patents
and Trademarks, Alexandria, Va 22313-1450,
on: July 10, 2006

Date of Transmission/Deposit
Signature
S. J. KIMBLE
D. KHARE

REPLY UNDER 37 C.F.R. §1.111

Sir:

In reply to the Office action of April 10, 2006, it is respectfully requested that the following remarks and the attached amendments¹⁾ be entered and considered for further prosecution of the above-identified application:

R E M A R K S

Claim 1 as set forth in Appendix I of this paper remains pending in this case. Claims 2 and 13 have been canceled, and Claim 1 has been amended, as indicated in the listing of the claims.

Accordingly, applicants have amended Claim 1 to recite that the composition is a neutraceutical, ie. a composition which includes only naturally occurring components capable of providing beneficial therapeutic and health promoting effects,²⁾ and have specified formula (I) based on page 6, indicated line 36, in conjunction with Table 1 on page 3 of the application.³⁾ No new matter has been added.

1) Cf. the Claim Amendments set forth in Appendix I on page 3 of this paper.

2) Cf. e.g. page 9, indicated lines 26 to 30, of the application.

3) Cf. the entries in line 2 of the table.

060710

- 1 -